SlideShare a Scribd company logo
IRON TOXICITY
By: CHANDAKA JYOTHI
18GT1T0004,
PHARM.D,4TH YEAR
SRI VENKATESWARA COLLEGE OF PHARMACY
CONTENTS:
• Introduction
• Epidemiology
• Physical appearance
• Uses/ source
• Fatal dose
• Clinical features
• Diagnosis
• Pathophysiolosy
• Toxicokinetics
• Treatment
• Reference
Introduction
• Iron is the fourth most abundant atomic element in the earth's crust and is found in the minerals hematite, magnetite, and siderite.
Biologically, iron is an essential element for most living organisms because it is a component or cofactor of many critical proteins such as
hemoglobin, myoglobin and enzymes such as catalase, xanthine oxidase, aconitase, reduced nicotinamide adenine dinucleotide,
ribonucleotide reductase, peroxidases, cytochrome oxidase etc.
Epidemiology of Iron Poisoning
•The American Association of Poison Control Centers (AAPCC) is a consortium of 66 regional poison control and information centers located throughout the
United States
• The AAPCC reported 1.5 million poisoning exposures for children and adolescents younger than 20 years.
•Children younger than 6 years accounted for 77% of the pediatric exposures and 50% of all reported exposures.
•Several reviews of poisoning hospitalizations suggest that iron poisoning is an infrequent cause of hospitalization;
the hospitalization rate for iron poisoning among children aged 0 to 4 years has been estimated at 8.7 per 100,000 children.
Physical Appearance of iron:
•Metallic iron is silvery white in colour, occurring naturally as haematite, magnetite, etc. and usually causes no problems.
• It is an essential element and deficiency results in anaemia.
• It is more than the required intake daily, the excess is excreted. But in some individuals with inborn errors, even normal dietary iron can cause toxic effects
due to accumulation, e.g. haemochromatosis (bronze diabetes).
• Iron salts are administered therapeutically in individuals with iron deficiency anaemia.
•Iron poisoning is related in most instances to overdose of iron salts.
•For instance ferrous sulfate (green vitriol) which occurs as bluish green crystals whereas ferric oxide, i.e. rust does not cause iron poisoning.
Uses/Sources:
Dietary Sources: The required daily amount of iron of 10–20 mg for adults is supplied through average diet.
• The required intake increases to 25–30 mg in pregnancy.
•The average daily intake for adults is 15 mg.
Environmental Sources: Iron is found in 5.1% of the earth’s crust.
• It is the second most abundant heavy metal, and the fourth most abundant element.
Industrial uses: Iron is used mainly in powder metallurgy and serves as a catalyst in chemical reactions.
• Iron is a component of carbon steels, cast iron, high-speed steels, high-strength low-alloy steels, manganese alloy steels, and stainless steels.
• Steel is the most important alloy of iron. It contains 0.25–2% of carbon. Alloyed with carbon (C), manganese (Mn), chromium (Cr), nickel (Ni) and other elements, iron is
used to form steel.
• Wrought iron is almost pure iron.
Other uses:
Iron uses include magnets, dyes, pigments, and abrasives.
Fatal dose:
The usual fatal dose corresponds to about 200 to 250 mg of elemental iron per kg of body weight. This can be calculated from the percentage of
elemental iron in a particular preparation, e.g. a single 150 mg tablet of anhydrous ferrous sulfate which contains 37% of elemental iron will
contain a total of 55 mg of elemental iron. But such calculations can be misleading since serious hepatotoxicity can result at much lower
concentrations of iron in the body which can lead to death
Clinical Features :
Most cases occur in children. There are 5 stages:
■ Stage I (0.5 to 2 hours) includes vomiting, haematemesis, abdominal pain, diarrhoea, haematochezia, lethargy, shock, acidosis, and coagulopathy. Necrosis
to the GI tract occurs from the direct effect of iron on GI mucosa. Severe gastrointestinal haemorrhagic necrosis with large losses of fluid and blood contribute
to shock. Free iron and ferritin produce vasodilatation that may also contribute to shock.
■ Stage II (after Stage I) includes apparent recovery and may contribute to a false sense of security. Observe closely.
■ Stage III (2 to 12 hours after Stage I) includes profound shock, severe acidosis, cyanosis and fever. Increased total peripheral resistance, decreased plasma
volume, haemoconcentration, decrease in total blood volume, hypotension, CNS depression, and metabolic acidosis have been reported.
■ Stage IV (2 to 4 days) includes possible hepatotoxicity, convulsions, and coma. Thought to be a direct action of iron on mitochondria. Monitor
liver function tests and bilirubin. Acute lung injury may also occur. The primary site of hepatic injury is the periportal areas of the hepatic lobule
(the principal site for hepatic regeneration), which may explain the increase in mortality and poorer prognosis. Iron induced hepatotoxicity is a
presumed result of free radical generation and lipid peroxidation. Iron catalyses hydroxyl radical formation (the most potent-free radical), which
initiates lipid peroxidation. Based on limited data, antioxidants may have a hepatoprotective role in iron poisoning.
■ Stage V (days to weeks) includes GI scarring and strictures. GI obstruction secondary to gastric or pyloric scarring may occur due to
corrosive effects of iron. Evaluate with barium contrast studies. Sustained-release preparations have resulted in small intestinal necrosis with
resultant scarring and obstruction.
Causes:
• There are several causes of iron poisoning, including overdose, iron overload, and genetic predisposition.
• Overdose
• Acute iron toxicity is usually the result of an accidental overdose.
• Most cases occur in children younger than 5 years old who accidentally eat iron supplements or adult multivitamins.
• Iron overload
• Iron overload is also known as chronic iron toxicity. Causes include:
• repeated blood transfusions to treat anemia.
• excessive iron therapy, either intravenously for anemia, or with supplements
• liver diseases, such as chronic hepatitis C or alcoholism
• Genetic causes
• Iron overload can occur naturally due to certain diseases. One example is hereditary hemochromatosis, which is a genetic condition that leads to
abnormally increased absorption of iron in the body from food.
Diagnosis:
1. x-ray: Like all other heavy metals, iron and its compounds are radiopaque. However, chewable iron tablets and liquid iron formulations
are usually not visualised on x-ray. Completely dissolved iron tablets/capsules may also not be radiopaque.
2. Serum iron level: Poisoning is indicated if this exceeds 150 mcg/100 ml, and serious toxicity is usually associated with levels beyond 500
to 600 mcg/100 ml. Peak levels are seen around 4 hours after ingestion. Measuring the total iron binding capacity and relating it to the
serum iron level is often misleading and unreliable.
3. Total leucocyte count (TLC), electrolytes, glucose, blood gas, clotting studies, liver function and renal function tests are useful estimates.
4. Chelation challenge test: Desferrioxamine in a dose of 25 mg/kg (maximum 1 gm) is given IM. If the serum iron has exceeded iron binding
capacity, the excess iron is chelated to desferrioxamine and the complex is excreted as a pinkish (vin rosé) colour in the urine (Fig 9.20). But a
negative result does not rule out iron poisoning.
5. Qualitative desferrioxamine colour test (QDCT): 2 ml of gastric fluid and 2 drops of 30% hydrogen peroxide are placed in 2 plastic tubes. 0.5
ml of solution of desferrioxamine (500 mg in 4 ml distilled water) is added into one tube and the resulting colour change is compared with the
other tube (control). If the test is positive, an orange to red colour will develop in the tube in which desferrioxamine was added. The test must be
done within 2 hours of ingestion of iron.
PATHOPHYSIOLOGY
Toxicokinetics:
Iron poisoning occurs when serum iron level exceeds the total iron-binding capacity (TIBC), resulting in free circulating iron in the bloodstream.
Mode of Action Free iron causes:
a. Massive postarteriolar dilatation which results in venous pooling.
b. b. Increased capillary permeability resulting in decreased plasma volume.
c. c. Oxidation of ferrous to ferric iron releasing hydrogen ions. Subsequent hydration of ferric iron results in metabolic acidosis.
d. d. Inhibits mitochondrial function leading to hepatic damage, hypoglycaemia, and hypoprothrombinaemia.
e. e. Inhibits thrombin-induced conversion of fibrinogen into fibrin.
f. f. Has a direct corrosive action on the GI mucosa.
Treatment:
1. Stomach wash with normal saline performed gently may be of benefit in massive ingestions. Desferrioxamine must not be used for lavage.
2. Activated charcoal is ineffective.
3. Magnesium hydroxide solution (1%) administered orally may help reduce absorption of iron by precipitating theformation of ferrous
hydroxide. Magnesium hydroxide and calcium carbonate containing antacids may safely be used in therapeutic doses to help reduce iron
absorption.
4. Obtain serum iron levels, creatinine, electrolytes, blood haemoglobin concentration, blood prothrombin time, baseline liver function tests, and
arterial blood gases in seriously poisoned patients.
5. Correction of hypovolaemia, and metabolic acidosis.
6. Chelation therapy:
a. This is indicated in any of the following situations:
• More than one episode of vomiting or diarrhoea.
• Significant abdominal pain, hypovolaemia, or acidosis.
• Multiple radio opacities on abdominal radiograph.
• Serum iron level greater than 350 mcg/100 ml.
b. Chelation can be done either with desferrioxamine (parenteral) or deferiprone (oral).
• Dose (desferrioxamine):
- Intravenous Dose: Administer by continuous infusion at a rate of up to 15 mg/kg/hr. Faster rates or IV boluses may cause hypotension in some individuals.
Infusion rates up to 35 mg/ kg/hr have been used in children with severe overdoses without adverse effects.
- Intramuscular Dose: Administer 90 mg/kg, up to a maximum of 1 gm/dose, every 8 hours as needed. Pain and induration at the injection site
are often experienced.
- Total Daily Dose: The recommended total intravenous or intramuscular daily dose should not generally exceed 6 grams.
- Duration of Infusion: Duration of infusion is guided by the patient’s clinical condition. Patients with moderate toxicity are generally treated for
8 to 12 hours, those with severe toxicity may require desferrioxamine for 24 hours or longer. Patients should be re-evaluated for evidence of
recurrent toxicity (hypotension, metabolic acidosis) several hours after the infusion is discontinued. Infusion duration of greater than 24 hours
has been associated with the development of ARDS.
Adverse Effects:
Sepsis: desferrioxamine induces Yersinia enterocolitica septicaemia and mucormycosis in children.
Visual Toxicity: Continuous intravenous administration of desferrioxamine produce visual toxicity (decreased visual acuity, night blindness,
colour blindness, retinal pigmentary abnormalities).
Sometimes Visual toxicity can be associated in patients with rheumatoid arthritis and chronic renal failure.
Ototoxicity:is risk factor of desferrioxamine (dose, duration of therapy and the presence of a low serum ferritin).
Reference:
• https://www.ncbi.nlm.nih.gov/books/NBK459224/
• https://www.healthline.com/health/iron-poisoning
• https://www.slideshare.net/MohammedALZahrani29/iron-toxicity-61259331
• https://www.ncbi.nlm.nih.gov/books/NBK459224/
• Modern Medical Toxicology,4th Edition by VV.Pillay

More Related Content

What's hot

Hematological Disorders - Bleeding Disorders
Hematological Disorders - Bleeding DisordersHematological Disorders - Bleeding Disorders
Hematological Disorders - Bleeding Disorders
Mohammed Aljaber
 
Tumor lysis syndrome
Tumor lysis syndromeTumor lysis syndrome
Tumor lysis syndrome
Karimkhaled19
 
Polycythemia
PolycythemiaPolycythemia
Polycythemia
HIRENGEHLOTH
 
Global Medical Cures™ | Blood disorders
Global Medical Cures™ | Blood disordersGlobal Medical Cures™ | Blood disorders
Global Medical Cures™ | Blood disorders
Global Medical Cures™
 
Anemia
AnemiaAnemia
Approach to anaemia
Approach to anaemiaApproach to anaemia
Approach to anaemia
PhocasBIMENYIMANA
 
Anemia in ckd patients dr. hamed ezzat
Anemia in ckd patients   dr. hamed ezzatAnemia in ckd patients   dr. hamed ezzat
Anemia in ckd patients dr. hamed ezzat
FarragBahbah
 
Polycythemia vera
Polycythemia veraPolycythemia vera
Polycythemia vera
Dilmo Yeldo
 
Polycythemia
PolycythemiaPolycythemia
Polycythemia
Ratheeshkrishnakripa
 
Role of erythropoitin in chronic kidney disease
Role of erythropoitin in chronic kidney diseaseRole of erythropoitin in chronic kidney disease
Role of erythropoitin in chronic kidney disease
Aftab Siddiqui
 
Polycythemia vera
Polycythemia vera Polycythemia vera
Polycythemia vera
М. Лхагва-Өлзий
 
Anemia ms3-mandernach
Anemia ms3-mandernachAnemia ms3-mandernach
Anemia ms3-mandernach
jasar
 
Hemochromatosis
HemochromatosisHemochromatosis
Hemochromatosis
MALAY RANJAN NAYAK
 
Genetic haemochromatosis
Genetic haemochromatosisGenetic haemochromatosis
Genetic haemochromatosis
SOUMYA SUBRAMANI
 
Rbcs & its clinical implications by Dr. Amit T. Suryawanshi, Oral Surgeon, P...
Rbcs & its clinical implications by Dr. Amit T. Suryawanshi,  Oral Surgeon, P...Rbcs & its clinical implications by Dr. Amit T. Suryawanshi,  Oral Surgeon, P...
Rbcs & its clinical implications by Dr. Amit T. Suryawanshi, Oral Surgeon, P...
All Good Things
 
Agape Jul 23 2009 Anemia I
Agape Jul 23 2009 Anemia IAgape Jul 23 2009 Anemia I
Agape Jul 23 2009 Anemia I
Tejas Desai
 
Drugs affecting haematopoiesis and recent advances by swaroopa
Drugs affecting haematopoiesis and recent advances by swaroopaDrugs affecting haematopoiesis and recent advances by swaroopa
Drugs affecting haematopoiesis and recent advances by swaroopa
SwaroopaNallabariki
 
Nephrotoxic drugs
Nephrotoxic drugsNephrotoxic drugs
Nephrotoxic drugs
Pravin Prasad
 
Drugs acting on blood and blood forming organs
Drugs acting on blood and blood forming organsDrugs acting on blood and blood forming organs
Drugs acting on blood and blood forming organs
Urmila Aswar
 
Hyperkalemia and its management
Hyperkalemia and its managementHyperkalemia and its management
Hyperkalemia and its management
MEEQAT HOSPITAL
 

What's hot (20)

Hematological Disorders - Bleeding Disorders
Hematological Disorders - Bleeding DisordersHematological Disorders - Bleeding Disorders
Hematological Disorders - Bleeding Disorders
 
Tumor lysis syndrome
Tumor lysis syndromeTumor lysis syndrome
Tumor lysis syndrome
 
Polycythemia
PolycythemiaPolycythemia
Polycythemia
 
Global Medical Cures™ | Blood disorders
Global Medical Cures™ | Blood disordersGlobal Medical Cures™ | Blood disorders
Global Medical Cures™ | Blood disorders
 
Anemia
AnemiaAnemia
Anemia
 
Approach to anaemia
Approach to anaemiaApproach to anaemia
Approach to anaemia
 
Anemia in ckd patients dr. hamed ezzat
Anemia in ckd patients   dr. hamed ezzatAnemia in ckd patients   dr. hamed ezzat
Anemia in ckd patients dr. hamed ezzat
 
Polycythemia vera
Polycythemia veraPolycythemia vera
Polycythemia vera
 
Polycythemia
PolycythemiaPolycythemia
Polycythemia
 
Role of erythropoitin in chronic kidney disease
Role of erythropoitin in chronic kidney diseaseRole of erythropoitin in chronic kidney disease
Role of erythropoitin in chronic kidney disease
 
Polycythemia vera
Polycythemia vera Polycythemia vera
Polycythemia vera
 
Anemia ms3-mandernach
Anemia ms3-mandernachAnemia ms3-mandernach
Anemia ms3-mandernach
 
Hemochromatosis
HemochromatosisHemochromatosis
Hemochromatosis
 
Genetic haemochromatosis
Genetic haemochromatosisGenetic haemochromatosis
Genetic haemochromatosis
 
Rbcs & its clinical implications by Dr. Amit T. Suryawanshi, Oral Surgeon, P...
Rbcs & its clinical implications by Dr. Amit T. Suryawanshi,  Oral Surgeon, P...Rbcs & its clinical implications by Dr. Amit T. Suryawanshi,  Oral Surgeon, P...
Rbcs & its clinical implications by Dr. Amit T. Suryawanshi, Oral Surgeon, P...
 
Agape Jul 23 2009 Anemia I
Agape Jul 23 2009 Anemia IAgape Jul 23 2009 Anemia I
Agape Jul 23 2009 Anemia I
 
Drugs affecting haematopoiesis and recent advances by swaroopa
Drugs affecting haematopoiesis and recent advances by swaroopaDrugs affecting haematopoiesis and recent advances by swaroopa
Drugs affecting haematopoiesis and recent advances by swaroopa
 
Nephrotoxic drugs
Nephrotoxic drugsNephrotoxic drugs
Nephrotoxic drugs
 
Drugs acting on blood and blood forming organs
Drugs acting on blood and blood forming organsDrugs acting on blood and blood forming organs
Drugs acting on blood and blood forming organs
 
Hyperkalemia and its management
Hyperkalemia and its managementHyperkalemia and its management
Hyperkalemia and its management
 

Similar to Iron toxicity ppt

Presentation on iron poisoning
Presentation on iron poisoningPresentation on iron poisoning
Presentation on iron poisoning
SiddiquaParveen
 
Iron Poisoning
Iron PoisoningIron Poisoning
Iron Poisoning
Elham Khaled
 
Iron toxicity
Iron toxicity Iron toxicity
Iron toxicity
Mohammed AL Zahrani
 
Trace elements in clinical chemistry
Trace elements in clinical chemistryTrace elements in clinical chemistry
Trace elements in clinical chemistry
Ofonmbuk Umoh
 
Cadmium iron toxicity
Cadmium iron toxicityCadmium iron toxicity
Cadmium iron toxicity
Amira Badr
 
Iron Poisoning.pptx
Iron Poisoning.pptxIron Poisoning.pptx
Iron Poisoning.pptx
rehamkarki39
 
Iron Toxicity. fe.pptx
Iron Toxicity. fe.pptxIron Toxicity. fe.pptx
Iron Toxicity. fe.pptx
VHARI5
 
HS-_Iron_Deficiency_Anemia.pdf
HS-_Iron_Deficiency_Anemia.pdfHS-_Iron_Deficiency_Anemia.pdf
HS-_Iron_Deficiency_Anemia.pdf
SanjayaManiDixit
 
iron deficiency anemia &Iron poisoning.pptx
iron deficiency anemia &Iron poisoning.pptxiron deficiency anemia &Iron poisoning.pptx
iron deficiency anemia &Iron poisoning.pptx
DR Venkata Ramana
 
Iron defciency anemia and recent advances in management
Iron defciency anemia and recent advances in managementIron defciency anemia and recent advances in management
Iron defciency anemia and recent advances in management
Chetan Ganteppanavar
 
Iron deficiency anemia
Iron deficiency anemiaIron deficiency anemia
Iron deficiency anemia
BRD Medical College, Gorakhpur
 
Approach to microcytic hypochromic anemia
Approach to microcytic hypochromic anemiaApproach to microcytic hypochromic anemia
Approach to microcytic hypochromic anemia
Shinjan Patra
 
Blood disease
Blood diseaseBlood disease
Blood disease
Zuhair Mustafa
 
Anemia, Pharmacotherapeutics, PharmD, RGUHS
Anemia, Pharmacotherapeutics, PharmD, RGUHSAnemia, Pharmacotherapeutics, PharmD, RGUHS
Anemia, Pharmacotherapeutics, PharmD, RGUHS
Amar Prasad
 
Iron chelators in treatment of iron overload syndromes
Iron chelators in treatment of iron  overload syndromesIron chelators in treatment of iron  overload syndromes
Iron chelators in treatment of iron overload syndromes
DR RML DELHI
 
Iron deficiency anaemia (for v year mbbs)
Iron deficiency anaemia (for v year mbbs)Iron deficiency anaemia (for v year mbbs)
Iron deficiency anaemia (for v year mbbs)
mona aziz
 
23.ppt
23.ppt23.ppt
23.ppt
Ernest Obese
 
23.ppt hxmljh bnszhgnbnb hhuehbuj nnhnjkjh
23.ppt hxmljh bnszhgnbnb hhuehbuj nnhnjkjh23.ppt hxmljh bnszhgnbnb hhuehbuj nnhnjkjh
23.ppt hxmljh bnszhgnbnb hhuehbuj nnhnjkjh
SARLSAICAMEDICALES
 
23.ppt
23.ppt23.ppt
Anemia - Types, Pathophysiology, Clinical Manifestations, Etiology, Treatment
Anemia - Types, Pathophysiology, Clinical Manifestations, Etiology, TreatmentAnemia - Types, Pathophysiology, Clinical Manifestations, Etiology, Treatment
Anemia - Types, Pathophysiology, Clinical Manifestations, Etiology, Treatment
Md Altamash Ahmad
 

Similar to Iron toxicity ppt (20)

Presentation on iron poisoning
Presentation on iron poisoningPresentation on iron poisoning
Presentation on iron poisoning
 
Iron Poisoning
Iron PoisoningIron Poisoning
Iron Poisoning
 
Iron toxicity
Iron toxicity Iron toxicity
Iron toxicity
 
Trace elements in clinical chemistry
Trace elements in clinical chemistryTrace elements in clinical chemistry
Trace elements in clinical chemistry
 
Cadmium iron toxicity
Cadmium iron toxicityCadmium iron toxicity
Cadmium iron toxicity
 
Iron Poisoning.pptx
Iron Poisoning.pptxIron Poisoning.pptx
Iron Poisoning.pptx
 
Iron Toxicity. fe.pptx
Iron Toxicity. fe.pptxIron Toxicity. fe.pptx
Iron Toxicity. fe.pptx
 
HS-_Iron_Deficiency_Anemia.pdf
HS-_Iron_Deficiency_Anemia.pdfHS-_Iron_Deficiency_Anemia.pdf
HS-_Iron_Deficiency_Anemia.pdf
 
iron deficiency anemia &Iron poisoning.pptx
iron deficiency anemia &Iron poisoning.pptxiron deficiency anemia &Iron poisoning.pptx
iron deficiency anemia &Iron poisoning.pptx
 
Iron defciency anemia and recent advances in management
Iron defciency anemia and recent advances in managementIron defciency anemia and recent advances in management
Iron defciency anemia and recent advances in management
 
Iron deficiency anemia
Iron deficiency anemiaIron deficiency anemia
Iron deficiency anemia
 
Approach to microcytic hypochromic anemia
Approach to microcytic hypochromic anemiaApproach to microcytic hypochromic anemia
Approach to microcytic hypochromic anemia
 
Blood disease
Blood diseaseBlood disease
Blood disease
 
Anemia, Pharmacotherapeutics, PharmD, RGUHS
Anemia, Pharmacotherapeutics, PharmD, RGUHSAnemia, Pharmacotherapeutics, PharmD, RGUHS
Anemia, Pharmacotherapeutics, PharmD, RGUHS
 
Iron chelators in treatment of iron overload syndromes
Iron chelators in treatment of iron  overload syndromesIron chelators in treatment of iron  overload syndromes
Iron chelators in treatment of iron overload syndromes
 
Iron deficiency anaemia (for v year mbbs)
Iron deficiency anaemia (for v year mbbs)Iron deficiency anaemia (for v year mbbs)
Iron deficiency anaemia (for v year mbbs)
 
23.ppt
23.ppt23.ppt
23.ppt
 
23.ppt hxmljh bnszhgnbnb hhuehbuj nnhnjkjh
23.ppt hxmljh bnszhgnbnb hhuehbuj nnhnjkjh23.ppt hxmljh bnszhgnbnb hhuehbuj nnhnjkjh
23.ppt hxmljh bnszhgnbnb hhuehbuj nnhnjkjh
 
23.ppt
23.ppt23.ppt
23.ppt
 
Anemia - Types, Pathophysiology, Clinical Manifestations, Etiology, Treatment
Anemia - Types, Pathophysiology, Clinical Manifestations, Etiology, TreatmentAnemia - Types, Pathophysiology, Clinical Manifestations, Etiology, Treatment
Anemia - Types, Pathophysiology, Clinical Manifestations, Etiology, Treatment
 

Recently uploaded

Netter's Atlas of Human Anatomy 7.ed.pdf
Netter's Atlas of Human Anatomy 7.ed.pdfNetter's Atlas of Human Anatomy 7.ed.pdf
Netter's Atlas of Human Anatomy 7.ed.pdf
BrissaOrtiz3
 
Integrating Ayurveda into Parkinson’s Management: A Holistic Approach
Integrating Ayurveda into Parkinson’s Management: A Holistic ApproachIntegrating Ayurveda into Parkinson’s Management: A Holistic Approach
Integrating Ayurveda into Parkinson’s Management: A Holistic Approach
Ayurveda ForAll
 
Does Over-Masturbation Contribute to Chronic Prostatitis.pptx
Does Over-Masturbation Contribute to Chronic Prostatitis.pptxDoes Over-Masturbation Contribute to Chronic Prostatitis.pptx
Does Over-Masturbation Contribute to Chronic Prostatitis.pptx
walterHu5
 
Best Ayurvedic medicine for Gas and Indigestion
Best Ayurvedic medicine for Gas and IndigestionBest Ayurvedic medicine for Gas and Indigestion
Best Ayurvedic medicine for Gas and Indigestion
Swastik Ayurveda
 
TEST BANK For An Introduction to Brain and Behavior, 7th Edition by Bryan Kol...
TEST BANK For An Introduction to Brain and Behavior, 7th Edition by Bryan Kol...TEST BANK For An Introduction to Brain and Behavior, 7th Edition by Bryan Kol...
TEST BANK For An Introduction to Brain and Behavior, 7th Edition by Bryan Kol...
rightmanforbloodline
 
OCT Training Course for clinical practice Part 1
OCT Training Course for clinical practice Part 1OCT Training Course for clinical practice Part 1
OCT Training Course for clinical practice Part 1
KafrELShiekh University
 
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
Holistified Wellness
 
Journal Article Review on Rasamanikya
Journal Article Review on RasamanikyaJournal Article Review on Rasamanikya
Journal Article Review on Rasamanikya
Dr. Jyothirmai Paindla
 
Hemodialysis: Chapter 4, Dialysate Circuit - Dr.Gawad
Hemodialysis: Chapter 4, Dialysate Circuit - Dr.GawadHemodialysis: Chapter 4, Dialysate Circuit - Dr.Gawad
Hemodialysis: Chapter 4, Dialysate Circuit - Dr.Gawad
NephroTube - Dr.Gawad
 
Efficacy of Avartana Sneha in Ayurveda
Efficacy of Avartana Sneha in AyurvedaEfficacy of Avartana Sneha in Ayurveda
Efficacy of Avartana Sneha in Ayurveda
Dr. Jyothirmai Paindla
 
Aortic Association CBL Pilot April 19 – 20 Bern
Aortic Association CBL Pilot April 19 – 20 BernAortic Association CBL Pilot April 19 – 20 Bern
Aortic Association CBL Pilot April 19 – 20 Bern
suvadeepdas911
 
Complementary feeding in infant IAP PROTOCOLS
Complementary feeding in infant IAP PROTOCOLSComplementary feeding in infant IAP PROTOCOLS
Complementary feeding in infant IAP PROTOCOLS
chiranthgowda16
 
Abortion PG Seminar Power point presentation
Abortion PG Seminar Power point presentationAbortion PG Seminar Power point presentation
Abortion PG Seminar Power point presentation
AksshayaRajanbabu
 
The Best Ayurvedic Antacid Tablets in India
The Best Ayurvedic Antacid Tablets in IndiaThe Best Ayurvedic Antacid Tablets in India
The Best Ayurvedic Antacid Tablets in India
Swastik Ayurveda
 
share - Lions, tigers, AI and health misinformation, oh my!.pptx
share - Lions, tigers, AI and health misinformation, oh my!.pptxshare - Lions, tigers, AI and health misinformation, oh my!.pptx
share - Lions, tigers, AI and health misinformation, oh my!.pptx
Tina Purnat
 
Top Effective Soaps for Fungal Skin Infections in India
Top Effective Soaps for Fungal Skin Infections in IndiaTop Effective Soaps for Fungal Skin Infections in India
Top Effective Soaps for Fungal Skin Infections in India
SwisschemDerma
 
Part II - Body Grief: Losing parts of ourselves and our identity before, duri...
Part II - Body Grief: Losing parts of ourselves and our identity before, duri...Part II - Body Grief: Losing parts of ourselves and our identity before, duri...
Part II - Body Grief: Losing parts of ourselves and our identity before, duri...
bkling
 
Top 10 Best Ayurvedic Kidney Stone Syrups in India
Top 10 Best Ayurvedic Kidney Stone Syrups in IndiaTop 10 Best Ayurvedic Kidney Stone Syrups in India
Top 10 Best Ayurvedic Kidney Stone Syrups in India
Swastik Ayurveda
 
Artificial Intelligence Symposium (THAIS)
Artificial Intelligence Symposium (THAIS)Artificial Intelligence Symposium (THAIS)
Artificial Intelligence Symposium (THAIS)
Josep Vidal-Alaball
 
Cardiac Assessment for B.sc Nursing Student.pdf
Cardiac Assessment for B.sc Nursing Student.pdfCardiac Assessment for B.sc Nursing Student.pdf
Cardiac Assessment for B.sc Nursing Student.pdf
shivalingatalekar1
 

Recently uploaded (20)

Netter's Atlas of Human Anatomy 7.ed.pdf
Netter's Atlas of Human Anatomy 7.ed.pdfNetter's Atlas of Human Anatomy 7.ed.pdf
Netter's Atlas of Human Anatomy 7.ed.pdf
 
Integrating Ayurveda into Parkinson’s Management: A Holistic Approach
Integrating Ayurveda into Parkinson’s Management: A Holistic ApproachIntegrating Ayurveda into Parkinson’s Management: A Holistic Approach
Integrating Ayurveda into Parkinson’s Management: A Holistic Approach
 
Does Over-Masturbation Contribute to Chronic Prostatitis.pptx
Does Over-Masturbation Contribute to Chronic Prostatitis.pptxDoes Over-Masturbation Contribute to Chronic Prostatitis.pptx
Does Over-Masturbation Contribute to Chronic Prostatitis.pptx
 
Best Ayurvedic medicine for Gas and Indigestion
Best Ayurvedic medicine for Gas and IndigestionBest Ayurvedic medicine for Gas and Indigestion
Best Ayurvedic medicine for Gas and Indigestion
 
TEST BANK For An Introduction to Brain and Behavior, 7th Edition by Bryan Kol...
TEST BANK For An Introduction to Brain and Behavior, 7th Edition by Bryan Kol...TEST BANK For An Introduction to Brain and Behavior, 7th Edition by Bryan Kol...
TEST BANK For An Introduction to Brain and Behavior, 7th Edition by Bryan Kol...
 
OCT Training Course for clinical practice Part 1
OCT Training Course for clinical practice Part 1OCT Training Course for clinical practice Part 1
OCT Training Course for clinical practice Part 1
 
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
 
Journal Article Review on Rasamanikya
Journal Article Review on RasamanikyaJournal Article Review on Rasamanikya
Journal Article Review on Rasamanikya
 
Hemodialysis: Chapter 4, Dialysate Circuit - Dr.Gawad
Hemodialysis: Chapter 4, Dialysate Circuit - Dr.GawadHemodialysis: Chapter 4, Dialysate Circuit - Dr.Gawad
Hemodialysis: Chapter 4, Dialysate Circuit - Dr.Gawad
 
Efficacy of Avartana Sneha in Ayurveda
Efficacy of Avartana Sneha in AyurvedaEfficacy of Avartana Sneha in Ayurveda
Efficacy of Avartana Sneha in Ayurveda
 
Aortic Association CBL Pilot April 19 – 20 Bern
Aortic Association CBL Pilot April 19 – 20 BernAortic Association CBL Pilot April 19 – 20 Bern
Aortic Association CBL Pilot April 19 – 20 Bern
 
Complementary feeding in infant IAP PROTOCOLS
Complementary feeding in infant IAP PROTOCOLSComplementary feeding in infant IAP PROTOCOLS
Complementary feeding in infant IAP PROTOCOLS
 
Abortion PG Seminar Power point presentation
Abortion PG Seminar Power point presentationAbortion PG Seminar Power point presentation
Abortion PG Seminar Power point presentation
 
The Best Ayurvedic Antacid Tablets in India
The Best Ayurvedic Antacid Tablets in IndiaThe Best Ayurvedic Antacid Tablets in India
The Best Ayurvedic Antacid Tablets in India
 
share - Lions, tigers, AI and health misinformation, oh my!.pptx
share - Lions, tigers, AI and health misinformation, oh my!.pptxshare - Lions, tigers, AI and health misinformation, oh my!.pptx
share - Lions, tigers, AI and health misinformation, oh my!.pptx
 
Top Effective Soaps for Fungal Skin Infections in India
Top Effective Soaps for Fungal Skin Infections in IndiaTop Effective Soaps for Fungal Skin Infections in India
Top Effective Soaps for Fungal Skin Infections in India
 
Part II - Body Grief: Losing parts of ourselves and our identity before, duri...
Part II - Body Grief: Losing parts of ourselves and our identity before, duri...Part II - Body Grief: Losing parts of ourselves and our identity before, duri...
Part II - Body Grief: Losing parts of ourselves and our identity before, duri...
 
Top 10 Best Ayurvedic Kidney Stone Syrups in India
Top 10 Best Ayurvedic Kidney Stone Syrups in IndiaTop 10 Best Ayurvedic Kidney Stone Syrups in India
Top 10 Best Ayurvedic Kidney Stone Syrups in India
 
Artificial Intelligence Symposium (THAIS)
Artificial Intelligence Symposium (THAIS)Artificial Intelligence Symposium (THAIS)
Artificial Intelligence Symposium (THAIS)
 
Cardiac Assessment for B.sc Nursing Student.pdf
Cardiac Assessment for B.sc Nursing Student.pdfCardiac Assessment for B.sc Nursing Student.pdf
Cardiac Assessment for B.sc Nursing Student.pdf
 

Iron toxicity ppt

  • 1. IRON TOXICITY By: CHANDAKA JYOTHI 18GT1T0004, PHARM.D,4TH YEAR SRI VENKATESWARA COLLEGE OF PHARMACY
  • 2. CONTENTS: • Introduction • Epidemiology • Physical appearance • Uses/ source • Fatal dose • Clinical features • Diagnosis • Pathophysiolosy • Toxicokinetics • Treatment • Reference
  • 3. Introduction • Iron is the fourth most abundant atomic element in the earth's crust and is found in the minerals hematite, magnetite, and siderite. Biologically, iron is an essential element for most living organisms because it is a component or cofactor of many critical proteins such as hemoglobin, myoglobin and enzymes such as catalase, xanthine oxidase, aconitase, reduced nicotinamide adenine dinucleotide, ribonucleotide reductase, peroxidases, cytochrome oxidase etc.
  • 4. Epidemiology of Iron Poisoning •The American Association of Poison Control Centers (AAPCC) is a consortium of 66 regional poison control and information centers located throughout the United States • The AAPCC reported 1.5 million poisoning exposures for children and adolescents younger than 20 years. •Children younger than 6 years accounted for 77% of the pediatric exposures and 50% of all reported exposures. •Several reviews of poisoning hospitalizations suggest that iron poisoning is an infrequent cause of hospitalization; the hospitalization rate for iron poisoning among children aged 0 to 4 years has been estimated at 8.7 per 100,000 children.
  • 5. Physical Appearance of iron: •Metallic iron is silvery white in colour, occurring naturally as haematite, magnetite, etc. and usually causes no problems. • It is an essential element and deficiency results in anaemia. • It is more than the required intake daily, the excess is excreted. But in some individuals with inborn errors, even normal dietary iron can cause toxic effects due to accumulation, e.g. haemochromatosis (bronze diabetes). • Iron salts are administered therapeutically in individuals with iron deficiency anaemia. •Iron poisoning is related in most instances to overdose of iron salts. •For instance ferrous sulfate (green vitriol) which occurs as bluish green crystals whereas ferric oxide, i.e. rust does not cause iron poisoning.
  • 6. Uses/Sources: Dietary Sources: The required daily amount of iron of 10–20 mg for adults is supplied through average diet. • The required intake increases to 25–30 mg in pregnancy. •The average daily intake for adults is 15 mg. Environmental Sources: Iron is found in 5.1% of the earth’s crust. • It is the second most abundant heavy metal, and the fourth most abundant element. Industrial uses: Iron is used mainly in powder metallurgy and serves as a catalyst in chemical reactions. • Iron is a component of carbon steels, cast iron, high-speed steels, high-strength low-alloy steels, manganese alloy steels, and stainless steels. • Steel is the most important alloy of iron. It contains 0.25–2% of carbon. Alloyed with carbon (C), manganese (Mn), chromium (Cr), nickel (Ni) and other elements, iron is used to form steel. • Wrought iron is almost pure iron. Other uses: Iron uses include magnets, dyes, pigments, and abrasives.
  • 7. Fatal dose: The usual fatal dose corresponds to about 200 to 250 mg of elemental iron per kg of body weight. This can be calculated from the percentage of elemental iron in a particular preparation, e.g. a single 150 mg tablet of anhydrous ferrous sulfate which contains 37% of elemental iron will contain a total of 55 mg of elemental iron. But such calculations can be misleading since serious hepatotoxicity can result at much lower concentrations of iron in the body which can lead to death
  • 8. Clinical Features : Most cases occur in children. There are 5 stages: ■ Stage I (0.5 to 2 hours) includes vomiting, haematemesis, abdominal pain, diarrhoea, haematochezia, lethargy, shock, acidosis, and coagulopathy. Necrosis to the GI tract occurs from the direct effect of iron on GI mucosa. Severe gastrointestinal haemorrhagic necrosis with large losses of fluid and blood contribute to shock. Free iron and ferritin produce vasodilatation that may also contribute to shock. ■ Stage II (after Stage I) includes apparent recovery and may contribute to a false sense of security. Observe closely. ■ Stage III (2 to 12 hours after Stage I) includes profound shock, severe acidosis, cyanosis and fever. Increased total peripheral resistance, decreased plasma volume, haemoconcentration, decrease in total blood volume, hypotension, CNS depression, and metabolic acidosis have been reported.
  • 9. ■ Stage IV (2 to 4 days) includes possible hepatotoxicity, convulsions, and coma. Thought to be a direct action of iron on mitochondria. Monitor liver function tests and bilirubin. Acute lung injury may also occur. The primary site of hepatic injury is the periportal areas of the hepatic lobule (the principal site for hepatic regeneration), which may explain the increase in mortality and poorer prognosis. Iron induced hepatotoxicity is a presumed result of free radical generation and lipid peroxidation. Iron catalyses hydroxyl radical formation (the most potent-free radical), which initiates lipid peroxidation. Based on limited data, antioxidants may have a hepatoprotective role in iron poisoning. ■ Stage V (days to weeks) includes GI scarring and strictures. GI obstruction secondary to gastric or pyloric scarring may occur due to corrosive effects of iron. Evaluate with barium contrast studies. Sustained-release preparations have resulted in small intestinal necrosis with resultant scarring and obstruction.
  • 10. Causes: • There are several causes of iron poisoning, including overdose, iron overload, and genetic predisposition. • Overdose • Acute iron toxicity is usually the result of an accidental overdose. • Most cases occur in children younger than 5 years old who accidentally eat iron supplements or adult multivitamins. • Iron overload • Iron overload is also known as chronic iron toxicity. Causes include: • repeated blood transfusions to treat anemia. • excessive iron therapy, either intravenously for anemia, or with supplements • liver diseases, such as chronic hepatitis C or alcoholism • Genetic causes • Iron overload can occur naturally due to certain diseases. One example is hereditary hemochromatosis, which is a genetic condition that leads to abnormally increased absorption of iron in the body from food.
  • 11. Diagnosis: 1. x-ray: Like all other heavy metals, iron and its compounds are radiopaque. However, chewable iron tablets and liquid iron formulations are usually not visualised on x-ray. Completely dissolved iron tablets/capsules may also not be radiopaque. 2. Serum iron level: Poisoning is indicated if this exceeds 150 mcg/100 ml, and serious toxicity is usually associated with levels beyond 500 to 600 mcg/100 ml. Peak levels are seen around 4 hours after ingestion. Measuring the total iron binding capacity and relating it to the serum iron level is often misleading and unreliable. 3. Total leucocyte count (TLC), electrolytes, glucose, blood gas, clotting studies, liver function and renal function tests are useful estimates.
  • 12. 4. Chelation challenge test: Desferrioxamine in a dose of 25 mg/kg (maximum 1 gm) is given IM. If the serum iron has exceeded iron binding capacity, the excess iron is chelated to desferrioxamine and the complex is excreted as a pinkish (vin rosé) colour in the urine (Fig 9.20). But a negative result does not rule out iron poisoning. 5. Qualitative desferrioxamine colour test (QDCT): 2 ml of gastric fluid and 2 drops of 30% hydrogen peroxide are placed in 2 plastic tubes. 0.5 ml of solution of desferrioxamine (500 mg in 4 ml distilled water) is added into one tube and the resulting colour change is compared with the other tube (control). If the test is positive, an orange to red colour will develop in the tube in which desferrioxamine was added. The test must be done within 2 hours of ingestion of iron.
  • 14.
  • 15.
  • 16.
  • 17.
  • 18.
  • 19.
  • 20.
  • 21.
  • 22.
  • 23.
  • 24. Toxicokinetics: Iron poisoning occurs when serum iron level exceeds the total iron-binding capacity (TIBC), resulting in free circulating iron in the bloodstream. Mode of Action Free iron causes: a. Massive postarteriolar dilatation which results in venous pooling. b. b. Increased capillary permeability resulting in decreased plasma volume. c. c. Oxidation of ferrous to ferric iron releasing hydrogen ions. Subsequent hydration of ferric iron results in metabolic acidosis. d. d. Inhibits mitochondrial function leading to hepatic damage, hypoglycaemia, and hypoprothrombinaemia. e. e. Inhibits thrombin-induced conversion of fibrinogen into fibrin. f. f. Has a direct corrosive action on the GI mucosa.
  • 25. Treatment: 1. Stomach wash with normal saline performed gently may be of benefit in massive ingestions. Desferrioxamine must not be used for lavage. 2. Activated charcoal is ineffective. 3. Magnesium hydroxide solution (1%) administered orally may help reduce absorption of iron by precipitating theformation of ferrous hydroxide. Magnesium hydroxide and calcium carbonate containing antacids may safely be used in therapeutic doses to help reduce iron absorption. 4. Obtain serum iron levels, creatinine, electrolytes, blood haemoglobin concentration, blood prothrombin time, baseline liver function tests, and arterial blood gases in seriously poisoned patients. 5. Correction of hypovolaemia, and metabolic acidosis.
  • 26. 6. Chelation therapy: a. This is indicated in any of the following situations: • More than one episode of vomiting or diarrhoea. • Significant abdominal pain, hypovolaemia, or acidosis. • Multiple radio opacities on abdominal radiograph. • Serum iron level greater than 350 mcg/100 ml. b. Chelation can be done either with desferrioxamine (parenteral) or deferiprone (oral). • Dose (desferrioxamine): - Intravenous Dose: Administer by continuous infusion at a rate of up to 15 mg/kg/hr. Faster rates or IV boluses may cause hypotension in some individuals. Infusion rates up to 35 mg/ kg/hr have been used in children with severe overdoses without adverse effects.
  • 27. - Intramuscular Dose: Administer 90 mg/kg, up to a maximum of 1 gm/dose, every 8 hours as needed. Pain and induration at the injection site are often experienced. - Total Daily Dose: The recommended total intravenous or intramuscular daily dose should not generally exceed 6 grams. - Duration of Infusion: Duration of infusion is guided by the patient’s clinical condition. Patients with moderate toxicity are generally treated for 8 to 12 hours, those with severe toxicity may require desferrioxamine for 24 hours or longer. Patients should be re-evaluated for evidence of recurrent toxicity (hypotension, metabolic acidosis) several hours after the infusion is discontinued. Infusion duration of greater than 24 hours has been associated with the development of ARDS.
  • 28. Adverse Effects: Sepsis: desferrioxamine induces Yersinia enterocolitica septicaemia and mucormycosis in children. Visual Toxicity: Continuous intravenous administration of desferrioxamine produce visual toxicity (decreased visual acuity, night blindness, colour blindness, retinal pigmentary abnormalities). Sometimes Visual toxicity can be associated in patients with rheumatoid arthritis and chronic renal failure. Ototoxicity:is risk factor of desferrioxamine (dose, duration of therapy and the presence of a low serum ferritin).
  • 29. Reference: • https://www.ncbi.nlm.nih.gov/books/NBK459224/ • https://www.healthline.com/health/iron-poisoning • https://www.slideshare.net/MohammedALZahrani29/iron-toxicity-61259331 • https://www.ncbi.nlm.nih.gov/books/NBK459224/ • Modern Medical Toxicology,4th Edition by VV.Pillay